Nutex Health (NUTX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $9.38
- EPS estimate
- $4.95
- EPS surprise
- +89.34%
- Revenue surprise
- −1.99%
- Revenue
- $210.8M
- Revenue estimate
- $215.0M
- Reported
- Aug 6, 2026
Nutex Health reported Q2 2026 results on August 6, 2026. Earnings per share were $9.38, ahead of the $4.95 estimate by 89.34%. Revenue was $210.8 million, slightly below the $215.0 million consensus. Compared with Q2 2025, the result swung from a loss of $2.95 per share to a profit, while revenue fell about 14% from $244.0 million.
The record is short: 15 quarters from Q3 2022, with no row for Q3 2025. Early quarters were losses, including a loss of $94.50 per share in Q3 2022 and a full-year 2023 loss of $12.00 per share. Results then changed sharply. Revenue jumped from $78.8 million in Q3 2024 to $257.6 million in Q4 2024, the highest in the table, and has stayed between $151.7 million and $257.6 million since. Full-year 2024 EPS came to $9.23, and the first half of 2026 adds up to $15.90. The company beat the EPS estimate in only five of the 15 quarters.
Nutex Health reported Q3 results between November 7 and November 18 in 2022, 2023 and 2024. That points to early or mid-November 2026 for the next report. It will show whether profits stay at the level of the first half.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | $4.95 | $9.38 | +89.34% | $210.8M | SEC |
| Q1 2026 | Apr 30, 2026 | $3.99 | $6.52 | +63.27% | $216.5M | SEC |
| Q4 2025 | Mar 5, 2026 | $5.56 | $3.11 | −44.03% | $151.7M | SEC |
| Q2 2025 | Aug 14, 2025 | −$1.43 | −$2.95 | −105.82% | $244.0M | SEC |
| Q1 2025 | May 13, 2025 | $3.04 | $2.56 | −15.88% | $211.8M | SEC |
| Q4 2024 | Mar 31, 2025 | −$0.12 | $11.12 | +9118.65% | $257.6M | SEC |
| Q3 2024 | Nov 7, 2024 | −$0.24 | −$1.72 | −616.67% | $78.8M | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.29 | −$0.07 | +75.86% | $76.1M | SEC |
| Q1 2024 | May 9, 2024 | $0.00 | −$0.10 | +0.00% | $67.5M | SEC |
| Q4 2023 | Mar 28, 2024 | $0.00 | −$7.50 | +0.00% | $69.7M | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.75 | −$1.50 | −100.00% | $62.7M | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.75 | −$1.50 | −100.00% | $58.9M | SEC |
| Q1 2023 | May 15, 2023 | −$2.25 | −$1.50 | +33.33% | $56.3M | SEC |
| Q4 2022 | Mar 2, 2023 | −$2.25 | −$3.00 | −33.33% | $53.7M | SEC |
| Q3 2022 | Nov 18, 2022 | $0.00 | −$94.50 | +0.00% | $28.4M | SEC |
Quarterly revenue
Frequently asked questions
When did Nutex Health (NUTX) last report earnings?
Nutex Health last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did NUTX beat earnings estimates?
Yes. Nutex Health reported EPS of $9.38 for Q2 2026 against a $4.95 estimate — a 89.34% beat.
How much revenue did NUTX report last quarter?
Nutex Health reported $210.8M in revenue for Q2 2026, against a consensus estimate of $215.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.